Syncromune

Syncromune is a US-based biopharmaceutical company developing a disruptive platform immunotherapy called SYNC-T, designed to optimize T cells and the immune system to attack cancer throughout the body. The company's personalized in situ combination multi-target cancer therapy aims to simultaneously address immune suppression mechanisms while also being immunostimulatory, leading to T cell activation and proliferation.